The first generic type of Sofosbuvir 400mg/Velpatasvir 100mg fixed-dose combination was introduced in Nepal by Natco Pharma Limited
The first generic type of Sofosbuvir 400mg/Velpatasvir 100mg fixed-dose combination was introduced in Nepal by Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816). Gilead Sciences, Inc, sells Sofosbuvir 400mg/Velpatasvir 100mg fixed-dose combination by the brand name Epclusa®.
Epclusa®, used for treating adults with genotype 1-6 chronic hepatitis C virus (HCV) infection, is the first available all-oral, pan-genotypic, single tablet treatment. Also, Epclusa is the first regimen available in one pill approved for treating patients with HCV genotype 2 and 3, that doesn’t require Ribavirin.
Natco plans to sell Sofosbuvir 400mg/Velpatasvir 100mg as VELPANAT ®. A 28-tablet bottle of VELPANAT generic version was priced in Nepal by Natco at an MRP of INR 25,000/- equivalent. Gilead Sciences, Inc., signed a non-exclusive licensing agreement with Natco to produce and market in 101 developing countries its generic treatments for chronic hepatitis C.